-
Mashup Score: 0
Quest Diagnostics is building out its artificial intelligence-powered cancer pathology offerings through a multilayered deal with PathAI—acquiring some assets and licensing out others. | Quest Diagnostics is building out its AI cancer pathology offerings through a multilayered deal with PathAI—acquiring some assets and licensing out others.
Source: www.fiercebiotech.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 4On doorstep of approval, Merck compares V116 pneumococcal vaccine to 1983 warhorse Pneumovax 23 - 3 day(s) ago
Five months ago, Merck & Co. | Five months ago, Merck revealed data that indicate its next-generation pneumococcal vaccine offers more protection for older adults than Pfizer’s market dominator Prevnar 20. Now, the company is comparing the investigational shot to its old warhorse, Pneumovax 23 (PPSV23).
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 4
Barinthus Biotherapeutics has hit the primary endpoint of a phase 1b/2 trial by showing its treatment for high-risk human papillomavirus (hrHPV)-associated cervical cancer is safe. | Barinthus Biotherapeutics has hit the primary endpoint of a phase 1b/2 trial by showing its treatment for high risk human papillomavirus-associated cervical cancer is safe. But the failure to prove the therapy actually works has left the biotech mulling how to take the candidate further.
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0
The FDA has handed out groundbreaking green lights to a pair of novel antibacterial coatings that each aim to keep implants as clean as possible during their short trip in the operating room from p | Though the initial green lights cover spine and orthopedic hardware, Orthobond and Onkos Surgical said their respective disinfectants could shield a wide variety of implants.
Source: www.fiercebiotech.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2
The FDA has handed out groundbreaking green lights to a pair of novel antibacterial coatings that each aim to keep implants as clean as possible during their short trip in the operating room from p | Though the initial green lights cover spine and orthopedic hardware, Orthobond and Onkos Surgical said their respective disinfectants could shield a wide variety of implants.
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0Precision medicine approach combining AI, DNA and drug testing shows gains against relapsed childhood cancers - 20 day(s) ago
Researchers have demonstrated that a functional precision medicine approach—combining artificial intelligence, DNA sequencing, mutation mapping and drug sensitivity testing—could feasibly help tack | The process, being developed by First Ascent Biomedical, showed promise in a small study published this week in Nature Medicine.
Source: www.fiercebiotech.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3Former bluebird execs hope to fly new startup to 'cutting edge' of gene therapy delivery tech - 20 day(s) ago
The untapped potential of gene editing therapies comes down to one major challenge: getting gene editors safely and efficiently into cells. | The untapped potential of gene editing therapies comes down to one major challenge: getting gene editors safely and efficiently into cells. Now, a new startup founded by two genetic medicine luminaries and run by former executives from bluebird bio is officially emerging from stealth mode to reveal its solutions to the industry.
Source: www.fiercebiotech.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 1Enlivex defends sepsis data that sank stock, shifting focus from mortality to subgroup analysis - 20 day(s) ago
Enlivex Therapeutics had a message Friday for investors who halved its share price: You’re misreading our data. | Enlivex Therapeutics had a message Friday for investors who halved its share price: You’re misreading our data. The cell therapy developer blamed imbalances between cohorts for the mixed results—and contended the effect on a small subgroup of sepsis patients suggests the candidate has a future.
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 21AACR: Cancer vaccines get a reintroduction as readouts support 'path forward' for the tech - 22 day(s) ago
A session at the American Association for Cancer Research (AACR) annual meeting posed a key question: Are cancer vaccines ready for prime time? | A session at the American Association for Cancer Research annual meeting asked a key question: Are cancer vaccines ready for prime time? If you ask Scott Kopetz, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, the answer is a quick yes.
Source: www.fiercebiotech.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2BrainStorm, plotting Lazerus-like recovery, aligns with FDA on design of phase 3b ALS trial - 23 day(s) ago
BrainStorm Cell Therapeutics is hauling itself off the mat for another run at amyotrophic lateral sclerosis (ALS). | BrainStorm Cell Therapeutics is hauling itself off the mat for another run at amyotrophic lateral sclerosis. A piece of the latest comeback strategy slotted into place Tuesday when the biotech revealed a written agreement with the FDA on the design of a phase 3b trial.
Source: www.fiercebiotech.comCategories: General Medicine News, Rare DiseaseTweet
.@QuestDX carves out @Path_AI #digitalpathology lab, plots #AI ramp-up | #pathology #diagnostics https://t.co/jd4BsDpe0L